Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Had completed the phase 2 dose-ranging study (i.e., the subject had completed the study visit at Week 12).~Exclusion Criteria:~* Had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase or alanine aminotransferase value 2.5 times or more of the upper reference limit at Week 8 of treatment in the phase 2 dose-ranging study).~* Had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dL or more at Week 8 of treatment in the phase 2 dose-ranging study).

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).